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Frataxin is a nuclear-encoded mitochondrial protein
which is deficient in Friedreich’s ataxia, a hereditary
neurodegenerative disease. Yeast mutants lacking the
yeast frataxin homologue (Yfh1p) show iron accumulation in mitochondria and increased sensitivity to oxidative stress, suggesting that frataxin plays a critical role
in mitochondrial iron homeostasis and free radical toxicity. Both Yfh1p and frataxin are synthesized as larger
precursor molecules that, upon import into mitochondria, are subject to two proteolytic cleavages, yielding
an intermediate and a mature size form. A recent study
found that recombinant rat mitochondrial processing
peptidase (MPP) cleaves the mouse frataxin precursor
to the intermediate but not the mature form (Koutnikova, H., Campuzano, V., and Koenig, M. (1998) Hum.
Mol. Gen. 7, 1485–1489), suggesting that a different peptidase might be required for production of mature size
frataxin. However, in the present study we show that
MPP is solely responsible for maturation of yeast and
human frataxin. MPP first cleaves the precursor to intermediate form and subsequently converts the intermediate to mature size protein. In this way, MPP could
influence frataxin function and indirectly affect mitochondrial iron homeostasis.

Recent studies have shown that the yeast frataxin homologue (YFH1, gene; Yfh1p, polypeptide) is a nuclear-encoded
mitochondrial protein (1– 4) and that its deficiency results in
mitochondrial iron overload (1, 2, 5), which in turn leads to
increased production of free radicals and loss of mitochondrial
function (1). Similarly, iron deposits (6), multiple mitochondrial enzyme deficiencies (7), and hypersensitivity to oxidative
stress (8) have been reported in studies on Friedreich’s ataxia
(FRDA),1 a recessively inherited neurodegenerative disease
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caused by a deficiency of human frataxin (9, 10). Thus, it is
believed that frataxin plays a critical role in mitochondrial iron
homeostasis and free radical toxicity and that this function is
conserved between yeast and mammals (7, 11). Not surprisingly, Yfh1p and mammalian frataxin share similar pathways
of mitochondrial import and processing. The Yfh1p precursor
(pYfh1p) is imported by isolated yeast mitochondria and processed to an intermediate (iYfh1p) and a mature size (mYfh1p)
form (12). Production of mYfh1p is impaired in mitochondria
isolated from yeast with mutations in the mitochondrial Hsp70
homologue Ssq1p, and similar to Yfh1p-deficient yeast (yfh1D)
(1, 2, 5), ssq1 mutants accumulate large amounts of mitochondrial iron (12), indicating that production of mYfh1p is required
for mitochondrial iron homeostasis. The mouse frataxin precursor is also cleaved twice, and missense mutations corresponding to those found in FRDA patients dramatically reduce
the efficiency of the second cleavage (13), further demonstrating the importance of proteolytic processing for frataxin function. Mitochondrial processing peptidase (MPP; EC 3.4.24.64)
(14) was shown to catalyze conversion of the mouse frataxin
precursor to intermediate form, but the peptidase responsible
for formation of mature frataxin was not identified (13). Additionally, it has not yet been established whether the intermediate forms of Yfh1p and frataxin represent productive intermediates, in that they are actually processed to the mature
form. In this study, we analyze proteolytic processing of Yfh1p
and human frataxin and demonstrate that both proteins are
processed to the mature form in two sequential steps by MPP.
EXPERIMENTAL PROCEDURES

Yeast Strains, Plasmids, and Media—The strains used in this study
are all isogenic derivatives of strain YPH501 (see Table I). Construction
of oct1D, yfh1D, and isogenic r0 strains was described previously (15,
16). For complementation of yfh1D by Yfh1p-myc, a polymerase chain
reaction fragment encoding the Yfh1p C terminus fused in-frame to the
9E10 c-myc epitope was synthesized using a sense oligonucleotide complementary to the YFH1 coding sequence upstream of a unique AccI site
and an antisense oligonucleotide specifying the 39-end of the YFH1
coding sequence, the 9E10 c-myc epitope coding sequence, a stop codon,
22 base pairs of the YFH1 39-flanking DNA, and a BamHI site. This
polymerase chain reaction product was substituted for the 39-region of
the YFH1 gene by digestion with AccI and BamHI, yielding a YFH1-myc
fusion construct. A centromeric TRP1-based YCplac22-YFH1-myc plasmid was then used to transform the yfh1D[YFH1] strain (16) and
replace the URA3-based YCp50-YFH1 plasmid, which was eliminated
by counterselection with 5-fluoroorotic acid, yielding the yfh1D[YFH1myc] strain.
Mitochondrial Fractionation—The yfh1D[YFH1-myc] strain was
grown in SSGD (6.7% bacto-yeast nitrogen base without amino acids,
0.3% yeast extract, 2% galactose, and 0.05% dextrose, supplemented
with amino acids and other growth requirements) at 30 °C to an A600 of
;2, spheroplasts were prepared and homogenized, and the nuclear
(1,000 3 g pellet), heavy (3,000 3 g pellet), and light (17,000 3 g pellet)
mitochondrial fractions were separated by differential centrifugation.
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The light mitochondrial fraction was resuspended at 2 mg protein/ml in
either isotonic (0.6 M mannitol, 20 mM HEPES-KOH, pH 7.4, 1 mg/ml
bovine serum albumin) or hypotonic (20 mM HEPES-KOH, pH 7.4, 1
mg/ml bovine serum albumin) buffer and incubated for 25 min at 4 °C
with gentle vortexing for 30 s every 5 min, essentially as described (17).
When indicated, this treatment was carried out in the presence of 100
mg/ml proteinase K, with or without 1% Triton X-100. Proteinase K
treatment was stopped by addition of 100 mM phenylmethylsulfonyl
fluoride. Mitochondria were then resuspended in 20 mM HEPES-KOH,
pH 7.4, 100 mM KCl and subjected to five cycles of freezing and thawing.
Finally, the disrupted organelles were separated into soluble (matrix)
and insoluble (membrane) fractions by centrifugation at 165,000 3 g.
Fractions were precipitated with 10% trichloroacetic acid (15), protein
concentration was determined by ultraviolet absorption (18), and aliquots were analyzed by SDS/PAGE, Western blotting, and chemiluminescence. Yfh1p was detected using a monoclonal antibody against the
9E10 c-myc epitope or a polyclonal antibody (16); frataxin was detected
using a polyclonal antibody against a GST-human frataxin fusion protein.2 Antisera against mitochondrial Hsp60 and cytochrome b2 (Cyt b2)
were gifts from other investigators.
Mitochondrial Import and Processing Assays—[35S]Methionine-labeled precursors were synthesized in vitro by coupled transcriptiontranslation (Promega). Previously described procedures were used for
isolation of yeast (19) and rat liver (20) mitochondria. Translation
mixture (6 ml) containing 35S-labeled precursor was incubated with
mitochondria (total protein, 80 mg) in import buffer (0.6 M mannitol, 20
mM HEPES-KOH, pH 7.4, 1 mM ATP, 1 mM MgCl2, 40 mM KCl, 5 mM
methionine, 3 mg/ml bovine serum albumin, 20 mM phosphocreatine,
and 200 mg/ml phosphocreatine kinase) for 20 min at 27 °C (15). Upon
import, reactions were either separated into mitochondrial pellet and
post-mitochondrial supernatant by centrifugation at 14,000 3 g for 5
min at 4 °C or first treated with proteinase K (250 mg/ml for 30 min at
0 °C) or trypsin (400 mg/ml for 5 min at 4 °C) and then separated into
pellet and supernatant in the presence of protease inhibitors. To dissipate the inner membrane potential, mitochondria were incubated with
30 mM carbonyl cyanide m-chlorophenyl-hydrazone for 5 min at 0 °C
prior to import. Crude matrix fractions were prepared by sonication of
mitochondria followed by centrifugation at 165,000 3 g for 30 min (15).
Recombinant yeast MPP was prepared essentially as described by Geli
(21); as determined by SDS/PAGE and Coomassie blue staining, the
final enzyme preparation contained only aMPP and bMPP subunits
(.99% purity).3 One unit of recombinant MPP was arbitrarily defined
as the amount of enzyme that converts 95% of the yeast F1-ATPase
subunit b precursor (pF1b) contained in 5 ml of translation mixture to
the mature form in 5 min at 27 °C in a total reaction volume of 50 ml of
10 mM HEPES-KOH (pH 7.4), 1 mM dithiothreitol, 1 mM MnCl2 (HDM
buffer). Import and processing reactions were directly analyzed by
SDS/PAGE and fluorography. For analysis of Yfh1p and human
frataxin processing, we used T 5 12.5% separating gels (total length,
12.5 cm) overlaid with T 5 4% stacking gels (T denotes the total
concentration of acrylamide and bisacrylamide), from a stock solution of
40:1.7 acrylamide:bisacrylamide; electrophoresis was started at 180 V,
shifted to 240 V after the samples had completely entered the separating gel, and continued for an additional 75 min (pYfh1p) or 30 min
(frataxin) after the samples had reached the bottom of the separating gel.
RESULTS AND DISCUSSION

To analyze mitochondrial import and processing of Yfh1p,
the YFH1 coding sequence was cloned into an in vitro expression vector, and radiolabeled pYfh1p was synthesized by coupled transcription-translation. SDS/PAGE analysis of the
translation mixture revealed a major band with an apparent
molecular mass of ;28 kDa, much larger than the predicted
size of pYfh1p (;19.5 kDa) (Fig. 1A, lane 1; lanes 8 and MW
show the mobility of pYfh1p relative to those of standard proteins). A difference of almost 10 kDa between the predicted
molecular mass and the electrophoretic mobility of pYfh1p was
reported previously (12), and similar discrepancies were noted
for human (10) and mouse (13) frataxin as well. Such differences are observed regardless of whether Yfh1p and frataxin
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P. Cavadini and F. Taroni, manuscript in preparation.
J. Adamec, unpublished results.

FIG. 1. Yfh1p is imported by isolated mitochondria, and localizes to the mitochondrial matrix in vivo. A, import of radiolabeled
pYfh1p into isolated yeast mitochondria. Lane 1, Yfh1p translation
mixture; lane 2, total import reaction; lane 3, mitochondrial pellet; lane
4, post-mitochondrial supernatant; lanes 5 and 6, as lanes 3 and 4,
respectively, with proteinase K added to the import reaction prior to its
separation into pellet and supernatant; lane 7, as lane 3, with carbonyl
cyanide m-chlorophenyl-hydrazone added to mitochondria before addition of translation mixture; lane 8, as lane 5; MW, molecular weight
markers. Samples were directly analyzed by 12.5% SDS/PAGE and
fluorography, as described under “Experimental Procedures”; for lanes
8 and MW, electrophoresis was stopped 75 min earlier. The letters p, i,
and m denote the precursor, intermediate, and mature forms of Yfh1p,
respectively. The arrowhead indicates a nonspecific product in the
translation mixture. B, import and processing of pYfh1p-myc by isolated mitochondria. Lanes 9 and 10 are as in panel A, lane 5, except that
radiolabeled pYfh1p-myc was used in lane 10. C, localization of mYfh1pmyc to the mitochondrial matrix. Mitochondria were isolated from
yfh1D[YC-YFH1-myc] yeast, and mitochondrial subfractions were analyzed by Western blotting. Anti-myc monoclonal antibody was used to
detect Yfh1p-myc, and specific antisera were used to detect endogenous
Hsp60 and Cyt b2, which were used as matrix and intermembrane space
markers, respectively. Yfh1p-myc was analyzed in one blot, and a second blot was used for analysis of both Hsp60 and Cyt b2. 250 mg of total
protein was loaded in lanes 11–15, and 90 mg was loaded in lanes 16 –19.
Lane 11, intact mitochondria; lane 12, intact mitochondria treated with
proteinase K; lane 13, mitochondria subjected to hypotonic shock and
reisolated by centrifugation; lane 14, mitochondria subjected to hypotonic shock in the presence of proteinase K and reisolated by centrifugation; lane 15, as lane 14, except that proteinase K treatment was
performed in the presence of Triton X-100 (this particular analysis was
not performed for Hsp60 and Cyt b2). Note that Cyt b2, a soluble
intermembrane space protein, remained associated with the mitochondria after hypotonic shock (lane 13) but became fully accessible to
proteinase K (lane 14), indicating that hypotonic treatment disrupted
but did not completely remove the outer mitochondrial membrane. Note
also that the levels of immunodetectable mYfh1p-myc were significantly increased after treatment with proteinase K (compare lanes 11
and 13 with lanes 12 and 14); because this was not observed for the
other proteins analyzed, it appears that clarification of the mitochondrial fraction by protease treatment somehow enhanced immunodetection of mYfh1p-myc. Lanes 16 and 17, intact mitochondria treated with
proteinase K (as in lane 12) subjected to repeated cycles of freezing and
thawing and separated into soluble (lane 16) and insoluble (lane 17)
fractions by ultracentrifugation. Lanes 18 and 19, mitochondria subjected to hypotonic shock in the presence of proteinase K (as in lane 14),
further subjected to repeated cycles of freezing and thawing, and separated into soluble (lane 18) and insoluble (lane 19) fractions. Attempts
to improve the dot-like appearance of the mYfh1p-myc band in lanes 16
and 18 were not successful due to a significant distortion of the protein
samples during electrophoresis in 12.5% SDS/PAGE.

are produced in intact cells or in vitro translation assays (Ref.
13 and this study), and therefore it seems unlikely that they
result from post-translational modifications. A more likely explanation is that the extremely hydrophilic nature of frataxin
causes it to bind less SDS as compared with standard proteins
of the same mass and that this results in lower electrophoretic
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TABLE I
S. cerevisiae strains
Strain

YPH501
Y6041 (wild type)
oct1D
yfh1D
yfh1D[YFH1]
yfh1D[YFH1-myc]
Isogenic r0

Genotype

MATa/a ura3–52/ura3–52 lys2–801
/lys2–801
his3-D200/his3-D200 leu2-D1/leu2-D1
MATa ura3–52 lys2–801amber ade2–101ochre trp1-D63
MATa ura3–52 lys2–801amber ade2–101ochre trp1-D63
MATa ura3–52 lys2–801amber ade2–101ochre trp1-D63
MATa ura3–52 lys2–801amber ade2–101ochre trp1-D63
MATa ura3–52 lys2–801amber ade2–101ochre trp1-D63
MATa ura3–52 lys2–801amber ade2–101ochre trp1-D63
amber

mobility. In agreement with this interpretation, we show in
this study that N-terminally deleted variants of Yfh1p migrate
in SDS/PAGE at rates slower than predicted from their molecular masses but proportional to the number of deleted amino
acids (see below).
Incubation of radiolabeled pYfh1p with isolated yeast mitochondria yielded two major processing products with apparent
molecular masses of ;27 kDa and ;21 kDa (designated intermediate (i), and mature (m), respectively) (Fig. 1A, lane 2; lanes
8 and MW show the mobilities of iYfh1p and mYfh1p relative to
those of standard proteins). Both iYfh1p and mYfh1p were
associated with the mitochondrial pellet (lane 3) and were
protected from externally added proteinase K (lane 5) but were
degraded when protease treatment was performed in the presence of Triton X-100 (not shown). When the inner membrane
potential was dissipated by addition of carbonyl cyanide mchlorophenyl-hydrazone prior to import, the precursor was still
associated with the mitochondrial pellet (lane 7) but was not
protected from proteinase K (not shown), nor were the two
processing products formed (lane 7). Thus, pYfh1p is specifically imported by isolated yeast mitochondria, and its translocation to a protease-protected compartment is associated with
two proteolytic events.
This pattern of processing sets pYfh1p apart from the vast
majority of mitochondrial protein precursors, which are cleaved
to the mature form in a single step by MPP (14). On the other
hand, two-step processing has been reported for precursors
targeted to the intermembrane space, which are cleaved sequentially by MPP and the inner membrane peptidase (IMP)
(22), as well as for a subset of precursors targeted to the matrix
or the inner membrane, which are processed by MPP and the
mitochondrial intermediate peptidase (MIP; EC 3.4.24.59) (15,
20). In light of this, and considering that MPP was shown to
catalyze conversion of the mouse frataxin precursor to intermediate form (13), we investigated whether IMP or MIP might
be involved in mYfh1p production. Because the proteins
cleaved by these peptidases are targeted to specific mitochondrial compartments, we sought to define the intramitochondrial localization of mYfh1p. Polyclonal antibodies against
Yfh1p were not available at the time of these experiments, and
therefore a sequence encoding the c-myc epitope (9E10) was
fused to the YFH1 coding sequence immediately upstream of
the stop codon. A centromeric YC-YFH1-myc plasmid was then
substituted for the YC-YFH1 plasmid in strain yfh1D[YFH1]
(Table I for strain genotypes), yielding yfh1D[YFH1-myc] derivatives that grew as well as the parental strain under a variety
of conditions (not shown), indicating that the c-myc epitope
does not affect Yfh1p function. Radiolabeled pYfh1p-myc was
efficiently imported by isolated mitochondria and was cleaved
to two products slightly larger than the iYfh1p and mYfh1p
products generated upon import of untagged precursor (Fig.
1B, lanes 9 and 10), demonstrating that the c-myc epitope does
not affect N-terminal processing of pYfh1p. Furthermore, it
was previously reported that Yfh1p fused to five copies of the
c-myc epitope localizes to mitochondria, as determined by im-

amber

Reference

ade2–101

his3-D200
his3-D200
his3-D200
his3-D200
his3-D200
his3-D200

ochre

ochre

/ade2–101

leu2-D1
leu2-D1
leu2-D1
leu2-D1
leu2-D1
leu2-D1

trp1-D63/trp1-D63

oct1D<LEU2
yfh1D<HIS3
yfh1D<HIS3 1 YC-YFH1
yfh1D<HIS3 1 YC-YFH1-myc
[rho0]

15
15
15
16
16
This study
16

munofluorescence staining (3). These data clearly indicate that
Yfh1p-myc is fully functional, and consequently its intramitochondrial localization must reflect that of the native protein.
We therefore isolated mitochondria from the yfh1D[YC-YFH1myc] strain and analyzed by Western blotting the Yfh1p-myc
distribution in mitochondrial subfractions. In intact mitochondria we detected a single protein band (Fig. 1C, lane 11) that
migrated identically to the mYfh1p-myc product formed upon
import of radiolabeled pYfh1p-myc into isolated mitochondria
(Fig. 1B, lane 10). Although the precursor form was not detected in vivo, overexposed blots did reveal low levels of iYfh1pmyc (not shown). The mYfh1p-myc product was associated with
intact mitochondria (Fig. 1C, lane 11) as well as mitochondria
subjected to hypotonic shock (to disrupt the outer mitochondrial membrane) (lane 13); furthermore, mYfh1p-myc was protected when mitochondria were subjected to proteinase K treatment (lane 12) or both hypotonic shock and proteinase K
treatment (lane 14). In contrast, mYfh1p-myc was fully degraded when proteinase K was added to mitochondria in the
presence of Triton X-100 (lane 15), indicating that protection of
mYfh1p-myc from protease treatment requires an intact inner
mitochondrial membrane. The mYfh1p-myc product was recovered in the soluble fraction derived from mitochondria that
were subjected to hypotonic shock and then repeated cycles of
freezing and thawing (to gently disrupt the inner membrane)
(lane 16). This was also the case when the soluble fraction was
derived from mitochondria that were subjected to both hypotonic shock and proteinase K treatment (to degrade any proteins external to the inner membrane) prior to freezing and
thawing (lane 18). This fractionation pattern was similar to
that of Hsp60, a soluble matrix protein (23), but different from
that of Cyt b2, a soluble intermembrane space protein (24) that
was fully accessible to proteinase K after hypotonic shock
(lanes 14 and 18). Furthermore, mYfh1p-myc partitioned differently from the Rieske iron-sulfur protein, an inner membrane protein (25) that was detected primarily in the membrane fractions (not shown). Thus, mYfh1p-myc behaved like a
soluble mitochondrial matrix protein, and this result was confirmed for endogenous mYfh1p using a polyclonal antibody (not
shown). Although localization to the matrix is consistent with
the hydrophilic nature of Yfh1p (2), Campuzano et al. (10)
showed by immunoelectronmicroscopy that human frataxin localizes at or near the inner mitochondrial membrane. Therefore, we cannot exclude the possibility that mYfh1p is loosely
bound to the inner mitochondrial membrane in intact mitochondria and that this interaction is disrupted when mitochondria are fractionated.
In any case, our results clearly indicate that mYfh1p is not
localized to the intermembrane space and therefore exclude the
possibility that IMP is involved in the maturation of Yfh1p. On
the other hand, the fact that mYfh1p localizes to the matrix is
consistent with the possibility that pYfh1p is processed in two
sequential steps by two matrix-localized peptidases, MPP and
MIP. Precursors cleaved by these two peptidases are characterized by a three-amino acid motif, RX2(F/L/I)XX(S/T/
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FIG. 2. pYfh1p is processed to the mature form in yeast lacking MIP activity. A, import and processing of radiolabeled pYfh1p by oct1D
mitochondria. Mitochondria isolated from wild-type, oct1D, and isogenic r0 yeast were incubated with Yfh1p translation mixture (T) for 20 min at
27 °C. Total import reactions were treated with proteinase K, and the mitochondrial pellet was reisolated by centrifugation and directly analyzed
by SDS/PAGE and fluorography. The letters p, i, and m and the arrowhead are as in the legend of Fig. 1A. B, import and processing of a
representative MIP substrate by oct1D mitochondria. Translation mixture containing radiolabeled CoxIV precursor (T) was incubated with isolated
mitochondria, and processing was analyzed as described above. The letters p, i, and m denote pCoxIV, iCoxIV, and mCoxIV, respectively. C,
detection of endogenous mYfh1p in oct1D yeast. Mitochondria were isolated from the strains indicated and aliquots analyzed by Western blotting
using a polyclonal antibody against Yfh1p. Lane 7, mitochondria isolated from yfh1D yeast, which lacks endogenous Yfh1p due to disruption of the
YFH1 gene. Lane 8, radiolabeled mYfh1p produced upon import of pYfh1p by isolated mitochondria, as in Fig. 2A, lane 1.

G)XXXX2, at the C terminus of their leader peptide (26 –28).
MPP initially cleaves these precursors two peptide bonds Cterminal to the Arg residue in the motif, yielding a processing
intermediate with a typical N-terminal octapeptide, which is
then specifically removed by MIP to yield the mature protein
(29). The N-terminal region of neither pYfh1p nor the frataxin
precursor contains this motif, however, suggesting that MIP is
not involved in their maturation. In fact, radiolabeled pYfh1p
was imported and processed to the mature form by mitochondria isolated from a knock-out mutant (oct1D) lacking yeast
MIP (OCT1, gene; YMIP, polypeptide)4 (Fig. 2A, lane 2). In
contrast, oct1D mitochondria did not cleave the intermediate
form of the cytochrome c oxidase subunit IV (iCoxIV) (Fig. 2B,
lane 2), which is normally processed to the mature form by
YMIP (15, 26). Interestingly, oct1D mitochondria produced less
mature protein than did wild-type mitochondria (Fig. 2A, compare lanes 1 and 2), and in this respect behaved identically to
mitochondria isolated from an isogenic r0 strain (lane 3). Similarly, pCoxIV was inefficiently processed by oct1D and r0 mitochondria (Fig. 2B, lanes 2 and 3), confirming that reduced
production of mYfh1p by oct1D mitochondria is not indicative of
a specific involvement of YMIP in pYfh1p processing. Rather,
this effect probably results from loss of mitochondrial DNA in
oct1D (26), a condition that is known to affect the efficiency of
in vitro import assays (30). In agreement with these in vitro
results, endogenous mYfh1p was detected by Western analysis
of mitochondria isolated from oct1D yeast (Fig. 2C, lane 5),
further demonstrating that YMIP is not directly involved in the
maturation of Yfh1p.
Having excluded direct participation of IMP or MIP in Yfh1p
processing, we tested the possibility that MPP might be solely
responsible for production of both iYfh1p and mYfh1p. To determine whether typical MPP cleavage sites (26 –28) are used
4
The open reading frame YKL134C, encoding the yeast mitochondrial intermediate peptidase, has recently been renamed OCT1 (YMIP,
polypeptide). OCT1 was previously referred to as MIP1 (15), but this
name was first assigned to open reading frame YOR330C.

in the processing of pYfh1p, we synthesized a series of Nterminally truncated versions of pYfh1p and used them as
standards to map the N termini of iYfh1p and mYfh1p. In our
SDS/PAGE system, iYfh1p ran slightly faster than a product
translated from residue 21 of pYfh1p (designated M-iYfh1p)
but slower than a product translated from residue 25 (Fig. 3).
Thus, the first cleavage site must lie between residues 21 and
25, and indeed residues 19 –22 (RYM 2I) match the consensus
sequence RX(X/Y)2(X/A/S), which is found at many MPP cleavage sites (26, 28) (Fig. 3). Similarly, mYfh1p ran between
products translated from residues 52 and 56, and residues
50 –53 (RFV2E) also match the RX(X/Y) 2(X/A/S) consensus
sequence (Fig. 3). Moreover, the amino acids C-terminal to this
putative MPP cleavage site include two serines and one threonine, which is consistent with observations that the mature N
termini of mitochondrial proteins frequently contain small hydroxylated residues (26, 28).
To confirm that pYfh1p is indeed processed in two steps by
MPP, radiolabeled pYfh1p was incubated with recombinant
yeast MPP, which was reconstituted from bacterially expressed
and purified subunits using a procedure similar to that described previously by Geli (21). After 10 min of incubation (Fig.
4A, lane 1), most of the input pYfh1p was no longer detected,
whereas iYfh1p was accumulated along with smaller amounts
of mYfh1p; incubation for an additional 10 min (lane 2) resulted
in increased production of mYfh1p with concomitant disappearance of iYfh1p. Given that most of the precursor was
converted to iYfh1p during the first 10 min of incubation (lane
1), we conclude that the mYfh1p accumulated in the subsequent 10 min (lane 2) was produced by cleavage of iYfh1p. The
fact that disappearance of the precursor band was not associated with a proportional increase in the intensity of the iYfh1p
and mYfh1p bands (lane 1) can be explained by the loss of three
of the four radiolabeled methionine residues present in the
precursor sequence (codons 1, 16, and 21) upon processing to
intermediate form (Fig. 3). On the other hand, iYfh1p and
mYfh1p are each predicted to contain a single methionine
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FIG. 3. Potential MPP cleavage sites
in the Yfh1p sequence. A series of
cDNAs encoding N-terminally truncated
forms of Yfh1p were generated by polymerase chain reaction, and the corresponding polypeptides synthesized by coupled
in vitro transcription-translation. 21 denotes a polypeptide translated from methionine 21 of the Yfh1p sequence (MiYfh1p); 25, 47, 52, and 56 denote
polypeptides translated from methionine
residues introduced at these positions of
the Yfh1p sequence (the N-terminal portion of which is shown at the bottom of the
figure). T, Yfh1p translation mixture;
Mito., mitochondrial pellets similar to
that in Fig. 2A, lane 1. The letters p, i, and
m and the arrowhead are as in the legend
of Fig. 1A.

FIG. 4. Two-step processing of pYfh1p by recombinant yeast MPP. A, processing of pYfh1p. 5 ml of pYfh1p translation mixture (T) were
incubated with 0.4 units of recombinant yeast MPP (MPP) in HDM buffer (total reaction volume, 20 ml), and 10-ml aliquots were withdrawn after
10 min (lane 1) and 20 min (lane 2) at 27 °C and directly analyzed by SDS/PAGE and fluorography. In two parallel reactions, pYfh1p was incubated
with 0.2 units of MPP (lane 3) or matrix (total protein, 6 mg) derived from wild-type yeast mitochondria (Matrix; lane 4) for 20 min at 27 °C in HDM
buffer (total reaction volume, 10 ml), and the processing reactions were analyzed as above. Lane 5, mitochondrial pellet similar to that in Fig. 2A,
lane 1. The letters p, i, and m and the arrowhead are as in the legend of Fig. 1A. B, processing of pCoxIV. 5 ml of pCoxIV translation mixture (T)
were incubated with 0.2 units of MPP (lane 6), wild-type matrix (total protein, 6 mg) (Matrix; lane 7), or matrix derived from oct1D mitochondria
(total protein, 6 mg) (oct1D matrix; lane 8) in a total reaction volume of 10 ml, as described above. The letters i and m are as in the legend of Fig.
2B. C, processing of pF1b. 5 ml of pF1b translation mixture (T) were incubated with 1 unit of MPP in a total reaction volume of 50 ml, and 10-ml
aliquots were withdrawn at the indicated time points. D, processing of M-iYfh1p. 5 ml of M-iYfh1p translation mixture (T) were incubated with 0.2
units of MPP (lane 14) or wild-type matrix (Matrix; lane 16) in a total reaction volume of 10 ml, as described above. Lane 15, mitochondrial pellet
similar to that in Fig. 2A, lane 1. The letters i and m are as in the legend of Fig. 1A; the arrowhead indicates a nonspecific product in the M-iYfh1p
translation mixture.

residue (codon 109), and disappearance of the accumulated
iYfh1p (lane 1) coincided with formation of an equal amount of
mYfh1p (lane 2). Apparently identical products were generated
whether pYfh1p was incubated with recombinant MPP (lanes
1–3), total mitochondrial matrix (lane 4), or isolated mitochondria (lane 5). It is important to note, however, that whereas
mYfh1p was efficiently produced in isolated mitochondria (lane
5), only trace amounts of mYfh1p were produced by matrix
(lane 4). Similarly, although 10-fold lower concentrations of
MPP were sufficient for processing of pYfh1p to iYfh1p, higher
enzyme levels and longer incubation times were required for
conversion of iYfh1p to mYfh1p (not shown). The possibility
that under these experimental conditions recombinant MPP

might have cleaved iYfh1p nonspecifically seems unlikely for
two reasons: first, under very similar conditions pCoxIV was
processed to intermediate form only (Fig. 4B, lane 6); and
second, pF1b was processed to the mature form after only 5 min
of incubation with MPP (Fig. 4C, lane 9), but no further proteolysis occurred during an additional 25 min of incubation at
27 °C (lanes 10 –13). Thus, a more likely explanation is that
whereas MPP per se is sufficient to catalyze conversion of
iYfh1p to mYfh1p, additional factors such as mitochondrial
membrane integrity may affect the efficiency of this reaction.
In fact, Knight et al. (12) showed previously that Ssq1p, a
mitochondrial Hsp70 homologue, is required for formation of
mYfh1p in vivo, suggesting that factors influencing the confor-
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FIG. 5. Processing of human frataxin by recombinant yeast MPP. A, 6 ml of translation mixture (T) containing [35S]methionine-labeled
human frataxin precursor was incubated with 2 units of MPP in a total reaction volume of 20 ml, and a 10-ml aliquot was withdrawn from the
processing reaction after 30 min at 27 °C (lane 1); one unit of MPP was added to the remainder of the reaction, and incubation continued for another
30 min (lane 2). Lane 3, mitochondrial pellet obtained by incubation of human frataxin precursor with freshly isolated rat liver mitochondria,
followed by trypsin treatment. Processing and import reactions were directly analyzed by SDS/PAGE and fluorography. Note that the frataxin
precursor used in this experiment contains an in-frame, C-terminal tag of 10 amino acids consisting of a methionine residue and the HA1 epitope.
The letters i and m denote the intermediate and mature forms of frataxin, respectively. The products indicated by the two arrowheads in lane 3
could be degradation products of frataxin, the significance of which remains to be established. MW, molecular weight markers. B, the following
samples were analyzed by SDS/PAGE and Western blotting: lane 4, 6 ml of human frataxin precursor translation mixture; lane 5, processing
reaction similar to that shown in Fig. 5A, lane 1, except that wild-type human frataxin precursor (i.e. lacking the C-terminal tag) was used; lane
6, 50 mg (total protein) of a human liver extract; lane 7, 1 unit of yeast MPP.

mation of iYfh1p may affect the rate of its conversion to mature
form.
To further confirm that mYfh1p is produced from iYfh1p, we
analyzed processing of the N-terminally truncated product
translated from residue 21 of pYfh1p (M-iYfh1p), which is
predicted to be one amino acid longer than iYfh1p (Fig. 3). We
found that M-iYfh1p was processed to the mature form very
efficiently by recombinant MPP (Fig. 4D, lane 14), and less
efficiently by matrix (lane 16), a processing pattern similar to
that observed for iYfh1p (Fig. 4A, lanes 3 and 4). The mature
size product generated by cleavage of M-iYfh1p in these reactions (lanes 14 and 16) was indistinguishable from the mYfh1p
produced upon import of pYfh1p into isolated yeast mitochondria (lane 15). This result provides further support to the
conclusion that MPP first cleaves the Yfh1p precursor to the
intermediate form and then converts this product to the mature form. Although two-step processing by MPP has been
described for at least one other mitochondrial protein precursor
(31), our observations do not agree with those of a previous
study in which recombinant rat MPP appeared to process the
precursor of mouse frataxin to the intermediate but not the
mature form (13). One possible explanation for this discrepancy
might be that rather than a purified enzyme, the previous
study used crude extracts of bacterial cells that co-expressed
both MPP subunits and perhaps a factor in these extracts
inhibited the second cleavage. To test this possibility, we
analyzed the processing of [35S]methionine-labeled human
frataxin precursor, the sequence of which is almost identical to
that of mouse frataxin (4). Because the human frataxin sequence does not contain any methionine residues C-terminal to
codon 76, we used a construct containing an in-frame C-termi-

nal tag of 10 amino acids that includes a methionine residue
(32). Upon incubation with recombinant yeast MPP, most of the
input precursor was converted to the intermediate form (Fig. 5,
lane 1); we also detected trace amounts of a smaller product
with a mobility similar to that reported for mature frataxin (13)
(lane 1). Addition of a fresh aliquot of MPP resulted in modestly
increased conversion of the accumulated intermediate to the
putative mature form (lane 2). This result was reproduced in
three independent experiments, and a very similar pattern of
processing was observed when the frataxin precursor was incubated with rat liver mitochondria (lane 3) or bacterially
expressed recombinant rat MPP (not shown). To exclude the
possibility that the C-terminal tag might interfere with cleavage of intermediate frataxin to the mature form, the wild-type
frataxin precursor (i.e. lacking the C-terminal tag) was incubated with yeast MPP as described above, and processing reactions were analyzed by Western blotting. As was the case for
the tagged precursor, we detected a major processing product
corresponding to the intermediate form of frataxin and only
trace amounts of the putative mature form (Fig. 5B, lane 5).
The latter product migrated identically to mature frataxin, as
detected in a variety of human tissue extracts (lane 6 and not
shown). Thus, under our experimental conditions, MPP did
efficiently cleave the frataxin precursor to the intermediate
form but could only partially process this intermediate to mature size protein. Given that the intermediate form of frataxin
was processed very inefficiently even upon import into rat
mitochondria (Fig. 5A, lane 3), it seems that similar to Yfh1p,
frataxin is processed in two sequential steps by MPP and that
species- and/or tissue-specific factors are involved in the second
cleavage.

Two-step Processing of Frataxin
A number of recent studies indicate that Yfh1p and frataxin
play conserved roles in mitochondrial iron homeostasis and
free radical toxicity (1– 8), supporting a model in which frataxin
deficiency results in oxidative damage, which in turn leads to
the degenerative lesions of FRDA (11). Moreover, the clinical
variability observed in FRDA patients suggests that additional
pathogenetic factors, such as mitochondrial proteins that interact with frataxin, may influence the phenotypic expression
of frataxin deficiency (11). MPP was previously identified as
the peptidase responsible for one of two cleavages required for
the biogenesis of mouse frataxin (13), and we have demonstrated that MPP is solely responsible for two-step processing
of yeast and human frataxin. Knight et al. (12) also identified
Ssq1p, a mitochondrial Hsp70 homologue, as an additional
factor required for cleavage of iYfh1p to mature form. Thus, it
is tempting to speculate that this pattern of processing has a
regulatory function and that genetic or environmental factors
that influence the affinity of MPP for the frataxin intermediate
might play a role in iron homeostasis and the clinical manifestations of FRDA.
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M. (1997) Nat. Genet. 16, 345–351
5. Radisky, D. C., Babcock, M. C., and Kaplan, J. (1999) J. Biol. Chem. 274,
4497– 4499
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